FDA orphan drug designation: treatment of spinal muscular atrophy (SMA) in patients 2 years of age and older
FDA orphan drug designation: treatment of spinal muscular atrophy (SMA) in patients 2 years of age and older
FDA orphan drug designation: treatment of Wilson’s disease